文献速递乳腺癌放疗放疗物理与技术

早期乳腺癌保乳术后CyberKnife部分乳腺照射:一项初步研究

Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer.
PubMed 文献 · Radiat Oncol · 2018-03-23

该初步研究评估了CyberKnife加速部分乳腺照射(CK-APBI)在早期乳腺癌保乳术后的可行性,共分析20例可评估患者并随访2年。主要终点为急性和亚急性毒性,次要终点为晚期毒性和美容效果。结果显示CK-APBI安全可行,毒性轻微,美容效果优良。

要点

  • CK-APBI处方剂量为30 Gy分5次照射PTV。
  • 急性和晚期毒性均为轻度,美容效果优良率患者评价从60%升至85%。
  • 该研究为初步可行性研究,样本量小,需进一步验证。

核心结论

  • CK-APBI在早期乳腺癌中安全可行,急性及晚期毒性轻微,美容效果非常好。

研究设计与样本

  • 前瞻性初步研究,从29例合格患者中纳入20例可评估患者,随访2年。

主要发现

  • 平均病理肿瘤大小为10.5 mm(±4.3,范围3-18),8例为LumA-like,11例为LumB-like,1例为LumB-HER2-enriched。
  • 使用Iris的CK-APBI治疗时间约60分钟(范围约35至约120分钟)。
  • 中位射束数为180(IQR 107-213;范围56-325),中位PTV等剂量线处方为86.0%(IQR 85.0-88.5;范围82-94)。
  • 中位PTV为88.1 cm3(IQR 63.8-108.6;范围32.3-238.8),中位乳房V100和V50分别为0.6(IQR 0.1-1.5;范围0-13)和18.6(IQR 13.1-21.7;范围7.5-37)。
  • 中位PTV最小剂量为26.2 Gy(IQR 24.7-27.6;范围22.3-29.3),观察期间仅记录到轻度副作用。

关键数值与推荐

  • 所有患者接受30 Gy分5次照射至PTV。
  • 美容评估由三位观察者从放疗开始至2年进行,患者评价优良率从60%逐步增至85%,与外部观察者趋势相似。

临床怎么用

  • 对于早期乳腺癌保乳术后患者,CK-APBI可作为部分乳腺照射的一种可行选择,但需注意该研究为初步结果。

局限性

  • 本研究为初步研究,样本量较小(20例可评估),随访时间仅2年,需更大样本和更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Local recurrences after breast conserving treatment are mainly close to the original tumor site, and as such shorter fractionation strategies focused on and nearest mammary gland, i.e. accelerated partial breast irradiation (APBI), have been developed. Stereotactic APBI has been attempted, although there is little experience using CyberKnife (CK) for early breast cancer. METHODS: This pilot study was designed to assess the feasibility of CK-APBI on 20 evaluable patients of 29 eligible, followed for 2 years. The primary endpoint was acute/sub-acute toxicity; secondary endpoints were late toxicity and the cosmetic result. RESULTS: Mean pathological tumor size was 10.5 mm (±4.3, range 3-18), 8 of these patients were classified as LumA-like, 11 as LumB-like, and 1 as LumB-HER2-enriched. Using CK-APBI with Iris, the treatment time was approximately 60 min (range~ 35 to ~ 120). All patients received 30 Gy in five fractions delivered to the PTV. The median number of beams was 180 (IQR 107-213; range:56-325) with a median PTV isodose prescription of 86.0% (IQR 85.0-88.5; range:82-94). The median PTV was 88.1 cm3 (IQR 63.8-108.6; range:32.3-238.8). The median breast V100 and V50 was 0.6 (IQR 0.1-1.5; range:0-13) and 18.6 (IQR 13.1-21.7; range:7.5-37), respectively. The median PTV minimum dose was 26.2 Gy (IQR 24.7-27.6; range 22.3-29.3). Mild side effects were recorded during the period of observation. Cosmetic evaluations were performed by three observers from the start of radiotherapy up to 2 years. Patients' evaluation progressively increase from 60% to 85% of excellent rating; this trend was similar to that of external observer. CONCLUSIONS: These preliminary results showed the safe feasibility of CK-APBI in early breast cancer, with mild acute and late toxicity and very good cosmetic results. TRIAL REGISTRATION: The present study is registered at Clinicaltrial.gov ( NCT02896322 ). Retrospectively egistered August 4, 2016.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lozza L, Fariselli L, Sandri M, et al. Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer. Radiat Oncol. 2018. PMID: 29566762. doi:10.1186/s13014-018-0991-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。